<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04291105</url>
  </required_header>
  <id_info>
    <org_study_id>VYR-VSV2-203</org_study_id>
    <nct_id>NCT04291105</nct_id>
  </id_info>
  <brief_title>Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients</brief_title>
  <official_title>Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Patients With Hepatocellular Carcinoma, Non-Small Cell Lung Cancer, Melanoma or Endometrial Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vyriad, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Regeneron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Vyriad, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2 study designed to determine the preliminary anti-tumor activity and confirm&#xD;
      the safety of VV1 in combination with cemiplimab. The study will concurrently enroll patients&#xD;
      with four distinct advanced malignancies in 5 separate tumor cohorts. The four cancers type&#xD;
      are NSCLC and melanoma that are progressing on CPI treatment, CPI-naïve HCC, and&#xD;
      treatment-naïve Endometrial.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with melanoma will be enrolled into two parallel cohorts; in one cohort (Intravenous&#xD;
      melanoma cohort) patients will receive IV VV1 and patients in the other cohort (Intratumoral&#xD;
      melanoma cohort) will receive both IV VV1 and Intratumoral VV1; both cohorts will receive IV&#xD;
      cemiplimab in combination therapy with VV1 treatment. Patients with NSCLC, HCC or endometrial&#xD;
      cancer will receive IV VV1 and IV cemiplimab combination therapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 24, 2020</start_date>
  <completion_date type="Anticipated">March 2023</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate (ORR) per imaging assessment</measure>
    <time_frame>within 24 months</time_frame>
    <description>Percentage of participants with objective response is assessed every six weeks from Cycle 1 Day 1 through disease progression, by investigator review based on RECIST version 1.1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events assessed by CTCAE v5.0</measure>
    <time_frame>within 24 months</time_frame>
    <description>Safety and tolerability</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentration time</measure>
    <time_frame>within 24 months</time_frame>
    <description>Serum concentration time data using RT-PCR of VSV-IFNβ-NIS and systemic cemiplimab levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To investigate the pharmacodynamics (PD) of VV1 by measuring serum IFNβ</measure>
    <time_frame>within 24 months</time_frame>
    <description>To investigate the pharmacodynamics (PD) of VV1 by measuring serum IFNβ expression</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">152</enrollment>
  <condition>Melanoma</condition>
  <condition>Hepatocellular Carcinoma</condition>
  <condition>Non Small Cell Lung Cancer</condition>
  <condition>Endometrial Cancer</condition>
  <arm_group>
    <arm_group_label>Melanoma intratumoral</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Melanoma, IV &amp; IT VV1 + cemiplimab Patients will receive both intravenous (IV) VV1 and intratumoral (IT) VV1 on Day 1. Will also receveive an infusion of cemiplimab on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Melanoma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Melanoma, IV + cemiplimab Patients will receive both IV VV1 and cemiplimab on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hepatocellular carcinoma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hepatocellular carcinoma Patients will receive both IV VV1 and cemiplimab on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-small cell lung cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Non-small cell lung cancer Patients will receive both IV VV1 and cemiplimab on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Endometrial cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Endometrial cancer Patients will receive both IV VV1 and cemiplimab on Day 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>VV1</intervention_name>
    <description>VV1 is to be administered on Day 1</description>
    <arm_group_label>Endometrial cancer</arm_group_label>
    <arm_group_label>Hepatocellular carcinoma</arm_group_label>
    <arm_group_label>Melanoma</arm_group_label>
    <arm_group_label>Melanoma intratumoral</arm_group_label>
    <arm_group_label>Non-small cell lung cancer</arm_group_label>
    <other_name>VSV-IFNβ-NIS, Voyager V1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Cemiplimab</intervention_name>
    <description>Cemiplimab should be given on Day 1 of each 21-day cycle for up to 2 years</description>
    <arm_group_label>Endometrial cancer</arm_group_label>
    <arm_group_label>Hepatocellular carcinoma</arm_group_label>
    <arm_group_label>Melanoma</arm_group_label>
    <arm_group_label>Melanoma intratumoral</arm_group_label>
    <arm_group_label>Non-small cell lung cancer</arm_group_label>
    <other_name>Libtayo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria&#xD;
&#xD;
          1. Age ≥18 years on day of signing informed consent.&#xD;
&#xD;
          2. Specific by tumor cohorts:&#xD;
&#xD;
               -  For the HCC cohort, confirmed diagnosis of inoperable HCC by histology or&#xD;
                  clinical/radiological criteria. Progressed on, or intolerant to, one prior line&#xD;
                  of systemic therapy. Child Pugh Score A or B7.&#xD;
&#xD;
               -  For the NSCLC cohort, histologically confirmed diagnosis of advanced and/or&#xD;
                  metastatic NSCLC in which radiological progression has been demonstrated during&#xD;
                  therapy with a PD(L)1 immune CPI and for which no existing options are felt to&#xD;
                  provide clinical benefit (only one line of PD-(L)1 therapy is permitted).&#xD;
                  Progression during or following 1 or more prior regimen(s) and no more than 3&#xD;
                  prior therapeutic regimens for metastatic disease.&#xD;
&#xD;
               -  For the melanoma cohorts, histologically confirmed diagnosis of advanced and/or&#xD;
                  metastatic melanoma in which radiological progression has been demonstrated&#xD;
                  during therapy with a PD(L)1 immune CPI and for which no existing options are&#xD;
                  considered to provide clinical benefit (only one line of PD(L)1 therapy is&#xD;
                  permitted). Progression on ipilimumab is not required. Note: For IT melanoma&#xD;
                  cohort:&#xD;
&#xD;
                    -  i. At least one tumor lesion amenable to repeated IT injection via palpation&#xD;
                       or ultrasound. Injection of deep visceral lesions is not permitted.&#xD;
&#xD;
                    -  ii. Agrees to provide a newly obtained biopsy of injected and witness&#xD;
                       lesions prior to start of study treatment, and to repeat biopsies twice&#xD;
                       during study treatment, and to providing the acquired tissue for biomarker&#xD;
                       analysis. Tissue obtained for the biopsy must not be previously irradiated,&#xD;
                       but a new or progressing lesion in the radiation field is acceptable.&#xD;
&#xD;
               -  For the endometrial cancer cohort, histologically confirmed diagnosis of advanced&#xD;
                  and/or metastatic endometrial adenocarcinoma. Eligible patients will have&#xD;
                  progressed on, or be intolerant to, one line of prior systemic therapy and are&#xD;
                  not candidates for curative surgery or radiation.&#xD;
&#xD;
          3. For patients treated with prior anti-PD-(L)1 therapy:&#xD;
&#xD;
               -  Last dose of anti-PD-(L)1 must be within 12 weeks of initiating study treatment.&#xD;
&#xD;
               -  Patient must have received at least 4 doses on q2w, 3 doses on q3w or 2 doses on&#xD;
                  q4w schedule of the previous anti-PD-(L)1 therapy.&#xD;
&#xD;
               -  Progression on prior anti-PD-(L)1 therapy must be defined by:&#xD;
&#xD;
               -  Documented radiographic progression on a single radiographic scan, if treatment&#xD;
                  with anti-PD-(L)1 was ≥ 16 weeks.&#xD;
&#xD;
               -  Documented radiographic progression on two consecutive radiographic scans at&#xD;
                  least 4 weeks apart, if treatment with anti-PD-(L)1 therapy was between 8 - 16&#xD;
                  weeks; if radiographic progression is accompanied with clinical progression, then&#xD;
                  a single scan assessment may be used.&#xD;
&#xD;
               -  If progression was only in lymph nodes, biopsy to provide histological&#xD;
                  confirmation of progression in the lymph node is required.&#xD;
&#xD;
          4. Measurable disease based on RECIST 1.1.&#xD;
&#xD;
        Key Exclusion criteria: Patients meeting any of the following exclusion criteria at&#xD;
        screening/Day -1 of first dosing will not be enrolled in the study&#xD;
&#xD;
          1. Availability of and patient acceptance of an alternative curative therapeutic option.&#xD;
&#xD;
          2. Recent or ongoing serious infection, including any active Grade 3 or higher per the&#xD;
             National Institute of Cancer Common Terminology Criteria for Adverse Events Version&#xD;
             5.0 (NCI CTCAE, v5.0) viral, bacterial, or fungal infection within 2 weeks of&#xD;
             registration.&#xD;
&#xD;
          3. Known seropositivity for and with active infection by the human immunodeficiency virus&#xD;
             (HIV).&#xD;
&#xD;
             • Patients who are seropositive for HIV but are receiving antiviral therapy and show&#xD;
             non-detectable viral load and a normal CD4 T cell count for at least 6 months are&#xD;
             eligible.&#xD;
&#xD;
          4. Seropositive for and with evidence of active viral infection with hepatitis B virus&#xD;
             (HBV). Patients who are hepatitis B surface antigen (HBsAg) negative and HBV viral DNA&#xD;
             negative are eligible.&#xD;
&#xD;
               -  Patients who had HBV but have received an antiviral treatment and show&#xD;
                  non-detectable viral DNA for 6 months are eligible.&#xD;
&#xD;
               -  Patients who are seropositive because of HBV vaccine are eligible.&#xD;
&#xD;
          5. Seropositive for and with active viral infection with hepatitis C virus (HCV).&#xD;
&#xD;
             • Patients who had HCV but have received an antiviral treatment and show no detectable&#xD;
             HCV viral DNA for 6 months are eligible.&#xD;
&#xD;
          6. Known history of active or latent TB (bacillus tuberculosis).&#xD;
&#xD;
          7. Any concomitant serious health condition, which, in the opinion of the investigator,&#xD;
             would place the patient at undue risk from the study, including uncontrolled&#xD;
             hypertension and/or diabetes, clinically significant pulmonary disease (e.g., chronic&#xD;
             obstructive pulmonary disease requiring hospitalization within 3 months) or&#xD;
             neurological disorder (e.g., seizure disorder active within 3 months).&#xD;
&#xD;
          8. Prior therapy within the following timeframe before the planned start of study&#xD;
             treatment as follows:&#xD;
&#xD;
               -  Small molecule inhibitors, and/or other investigational agent: ≤ 2 weeks or 5&#xD;
                  half-lives, whichever is shorter.&#xD;
&#xD;
               -  Chemotherapy, other monoclonal antibodies, antibody-drug conjugates, or other&#xD;
                  similar experimental therapies: ≤ 3 weeks or 5 half-lives, whichever is shorter.&#xD;
&#xD;
               -  Antibody drug conjugates and radioimmunoconjugates or other similar experimental&#xD;
                  therapies ≤ 6 weeks or 5 half-lives, whichever is shorter.&#xD;
&#xD;
          9. New York Heart Association (NYHA) classification III or IV, known symptomatic coronary&#xD;
             artery disease, or symptoms of coronary artery disease on systems review, or known&#xD;
             cardiac arrhythmias (atrial fibrillation or supraventricular tachycardia).&#xD;
&#xD;
         10. Any known or suspected active organ-threatening autoimmune disease, such as&#xD;
             inflammatory bowel disease, autoimmune hepatitis, lupus, or pneumonitis, with the&#xD;
             exception of hypothyroidism and type 1 diabetes that are controlled with treatment.&#xD;
&#xD;
         11. Immunodeficiency or immunosuppression&#xD;
&#xD;
         12. History of Grade 3 or 4 immune-mediated adverse reaction to immune CPIs.&#xD;
&#xD;
         13. Toxicities from previous therapies that have not resolved to a Grade 1 or less.&#xD;
&#xD;
         14. History of non-infectious pneumonitis that required steroids, or current pneumonitis.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alice Bexon, MD</last_name>
    <role>Study Chair</role>
    <affiliation>CMO</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Naimish Pandya, MD</last_name>
    <role>Study Director</role>
    <affiliation>Clinical Lead</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Steve Kaesshaefer</last_name>
    <phone>+19737152917</phone>
    <email>steve.kaesshaefer@Bexonclinical.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Barbara Duckett</last_name>
    <phone>5072890944</phone>
    <email>bduckett@vyriad.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mayo Clinical</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Referral Office</last_name>
      <phone>855-776-0015</phone>
    </contact>
    <investigator>
      <last_name>Mitesh Borad, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>City of Hope Medical Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daneng Li, MD</last_name>
      <phone>626-471-9200</phone>
    </contact>
    <investigator>
      <last_name>Deneng Li, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>USC Norris Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lorraine Martinez</last_name>
      <email>Lorraine.Martinez@med.usc.edu</email>
    </contact>
    <investigator>
      <last_name>Anthony El-Khoueiry, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HOAG Memorial Hospital Presbyterian</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leila Andres</last_name>
      <email>leila.andres@hoag.org</email>
    </contact>
    <investigator>
      <last_name>Anthony El-Khoueiry, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint John's Health Center - John Wayne Cancer Institute (JWCI)</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Stanford Health Care</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520-8032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Neta Shanwetter Levit, MPH</last_name>
      <phone>203-500-0834</phone>
      <email>Neta.shanwetterlevit@yale.edu</email>
    </contact>
    <contact_backup>
      <last_name>Barbara Johnson</last_name>
      <email>barbara.johnson@yale.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Mario Sznol, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Georgetown University Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Wagner, RN</last_name>
      <phone>202-687-9782</phone>
      <email>sw1095@georgetown.edu</email>
    </contact>
    <investigator>
      <last_name>Ruth He, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinical</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Referral Office</last_name>
      <phone>855-776-0015</phone>
    </contact>
    <investigator>
      <last_name>Kabir Mody, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashley Kaufman</last_name>
      <email>a.kaufman@med.miami.edu</email>
    </contact>
    <contact_backup>
      <last_name>Christy Estevez</last_name>
      <email>cme101@med.miami.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Jose Lutzky, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ochsner Clinic Foundation</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amanda Woolery, RN, BSN</last_name>
      <phone>504-842-0275</phone>
      <email>amanda.woolery@ochsner.org</email>
    </contact>
    <investigator>
      <last_name>Daniel Johnson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital Cancer Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oladapo Yeku, MD, PhD</last_name>
      <phone>617-643-9354</phone>
      <email>oyeku@mgh.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Oladapo Yeku, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Masonic Cancer Center, University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Information Hotline</last_name>
      <phone>612-624-2620</phone>
      <email>ccinfo@umn.edu</email>
    </contact>
    <investigator>
      <last_name>Manish Patel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Referal Office</last_name>
      <phone>855-776-0015</phone>
    </contact>
    <investigator>
      <last_name>Alex Adjei, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Billings Clinic Montana Cancer Consortium</name>
      <address>
        <city>Billings</city>
        <state>Montana</state>
        <zip>59101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathy Wilkinson</last_name>
      <phone>406-435-7415</phone>
      <email>kwilkinson@billingsclinic.org</email>
    </contact>
    <investigator>
      <last_name>Justin Bottsford-Miller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Atlantic Health</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07960</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Angela Alistar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rutgers Cancer Institute of New Jersey</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jyoti Malhorta, MD</last_name>
      <phone>732-235-2465</phone>
      <email>jm1940@cinj.rutgers.edu</email>
    </contact>
    <investigator>
      <last_name>Jyoti Malhotra, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashley Poliak Hammad, MSN</last_name>
      <phone>212-824-7309</phone>
      <email>Ashley.hammad@mssm.edu</email>
    </contact>
    <investigator>
      <last_name>Thomas Marron, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Trisha Wise-Draper, MD, PhD</last_name>
      <phone>513-584-7698</phone>
      <email>cancer@uchealth.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>UPMC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Krystle Eaton, BSN</last_name>
      <phone>412-623-7957</phone>
      <email>mientkiewiczk@upmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Amy Rose</last_name>
      <email>kennaj@UPMC.EDU</email>
    </contact_backup>
    <investigator>
      <last_name>Sarah Taylor, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sanford Cancer Center</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Staci Vogel</last_name>
      <phone>605-312-3320</phone>
      <email>staci.vogel@sanfordhealth.org</email>
    </contact>
    <investigator>
      <last_name>Steven Powell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UT Health San Antonio MD Anderson Cancer Center</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Epp Goodwin</last_name>
      <phone>210-450-5798</phone>
      <email>goodwine@uthscsa.edu</email>
    </contact>
    <investigator>
      <last_name>John Sarantopolos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>February 25, 2020</study_first_submitted>
  <study_first_submitted_qc>February 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 2, 2020</study_first_posted>
  <last_update_submitted>July 6, 2021</last_update_submitted>
  <last_update_submitted_qc>July 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Solid Tumor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Endometrial Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cemiplimab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

